IP Library Granted Patent US 11,116,754
Granted Patent B2
US 11,116,754 · App. 15/774,403 · Granted Sep 14, 2021

Inhibition of TOR complex 2 increases immunity against bacterial infection

Inventors: Michele Shirasu-Hiza (New York, NY); Julie Canman (New York, NY)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A61K31/436A61K31/4745A61K31/519A61K31/715A61K31/7105A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,116,754
App. No.
15/774,403
Granted
Sep 14, 2021
Kind
B2
Abstract

This invention relates to methods and compositions for increasing immunity against, and survival of, a bacterial infection by inhibiting Target of Rapamycin (TOR) complex 2 or TORC 2. In particular, the current invention is useful in increasing immunity and survival after infection by Burkholderia cepacia as well as other bacteria since the agents that target TORC2 increase host tolerance of infection rather than target the clearance or containment of specific types of bacteria. This invention also relates to methods and compositions for increasing immunity against, survival of, and host tolerance to a bacterial infection by inhibiting the circadian regulator, Period protein.

Claims (4)

1. A method of increasing survival of an infection caused by Burkholderia cepacia , comprising administering to a subject in need thereof, a therapeutically effective amount of a small molecule that inhibits TOR complex 2, wherein the small molecule is chosen from the group consisting of Torin 1, Torin 2, torkinib (PP242), PP30, Ku-0063794, WAY-600, WYE-687, WYE-354, AZD8055, INK128, OS1027, AZD2014, omipalisib, wortmannin, LY294002, PI-103, BGT226, XL765, and NVP-BEZ235.

2. The method of claim 1 , wherein the agent does not inhibit TOR complex 1.

3. A method of increasing survival and immunity to Burkholderia cepacia , comprising administering to a subject in need thereof, a therapeutically effective amount of an agent that inhibits TOR complex 2, wherein the agent is chosen from the group consisting of Torin 1, Torin 2, torkinib (PP242), PP30, Ku-0063794, WAY-600, WYE-687, WYE-354, AZD8055, INK128, OS1027, AZD2014, omipalisib, wortmannin, LY294002, PI-103, BGT226, XL765, and NVP-BEZ235.

4. The method of claim 3 , wherein the agent does not inhibit TOR complex claim 1 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 6, 2023
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062652/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: SHIRASU-HIZA, MICHELE; CANMAN, JULIE
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 045743/0351 →
Continuity (2)
Provisional Application 62254957 · Nov 13, 2015
Related Publication 20200281902A1 · Sep 10, 2020